Table 5.
Current clinical trials of LNP@mRNA.
| Institution | Name | Indication | mRNA Encoding | Route of Administration | Delivery Vector | Clinical Trial Number (Phase) |
|---|---|---|---|---|---|---|
| ModernaTX, Inc. | mRNA-1647 | Cytomegalovirus (CMV) Infection | Human cytomegalovirus envelope glycoprotein H | i.m. | LNP V1GL |
NCT03382405 (I) NCT04232280 (II) |
| mRNA-1443 | LNP | NCT03382405 (I) | ||||
| mRNA-1653 | Human metapneumovirus (hMPV) and human parainfluenza 3 virus (PIV3) | hMPV and PIV3 membrane fusion protein | i.m. | LNP |
NCT03392389 (I) NCT04144348 (I) |
|
| VAL-506440; mRNA-1440 | Influenza A virus (H10N8) | Influenza hemagglutinin H10N8 | i.m. | LNP | NCT03076385 (I) | |
| VAL-339851; mRNA-1851 | Influenza A virus (H7N9) | Influenza hemagglutinin H7N9 | i.m. | LNP | NCT03345043 (I) | |
| mRNA-1345 | Respiratory syncytial virus (RSV) | RSV pre-infused F protein | i.m. | LNP | NCT04528719 (I) | |
| VAL-181388; mRNA-1388; | Chikungunya virus (CHIKV) | Anti-CHKV monoclonal antibody | i.m. | LNP | NCT03325075 (I) | |
| mRNA-1944 | Prevention of CHIKV infection | CHIKV-specific monoclonal neutralizing antibody (CHKV-24) | i.m. | LNP | NCT03829384 (I) | |
| mRNA-1325; | Zika virus | PrM and E | i.m. | LNP | NCT03014089 (I) | |
| mRNA-1893 | i.m. | LNP V1GL | NCT04064905 (I) | |||
| mRNA-2752 | Solid tumor malignancies or lymphoma/ovarian cancer | Human OX40L, IL-23, and IL-36γ | Intratumoral injection | LNP | NCT03739931 (1) | |
| mRNA-2416 | Human OX40L | Intratumoral injection | LNP | NCT03323398 (I/II) | ||
| mRNA-4157 | Melanoma | Personalized | i.m. | LNP |
NCT03897881 (II) |
|
| Solid tumors | Personalized | i.m. | LNP | NCT03313778 (I) | ||
| BioNTech SE | Lipo-MERIT | Melanoma | Four selected malignant melanoma-associated antigens: New York-ESO 1 (NY-ESO-1), tyrosinase, melanoma-associated antigen A3 (MAGE-A3), and trans-membrane phosphatase with tensin homology (TPTE) | i.m. | Lipoplex | NCT02410733 (I) |
| CureVac | CV7202 | Rabies | Rabies virus glycoprotein (RABV-G) | i.m. | LNP | NCT03713086 (I) |
| GlaxoSmithKline | RG-SAM (CNE) vaccine (GSK3903133A) | Viral diseases | Rabies glycoprotein G (RG) | i.m. | CNE | NCT04062669 (I) |